Hit-To-Lead, London, UK
Event Jul 18
Enhancing lead generation to accelerate quality compounds into lead optimisation
Increasing pressure to reduce attrition and put forward better quality lead compounds is forcing hit-to-lead up the agenda of every pharmaceutical company. Many are now reducing this major bottleneck by improving decision-making and generating better quality leads faster. And Pharma IQ is showcasing the most innovative and successful case studies at this year’s Hit-to-Lead conference. Leaders from big pharma including Pfizer, Roche, Novartis, AstraZeneca, Bayer, Wyeth, Merck, Sanofi-Aventis and Johnson & Johnson will be revealing their stories of success and failure in lead generation. By taking a practical and in-depth look at their strategies and experiences, you can enhance your own practices and ensure you are focussing your resources only on the most promising compounds.
To register ring +44 (0)207 368 9300 or go to http://www.iqpc-pharma.com/GB-2484/HTS quoting your priority code HTS
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018